Dual specific phosphatase 12 ameliorates cardiac hypertrophy in response to pressure overload

被引:17
作者
Li, Wei-ming [1 ]
Zhao, Yi-fan [1 ]
Zhu, Guo-fu [1 ]
Peng, Wen-hui [1 ]
Zhu, Meng-yun [1 ]
Yu, Xue-jing [1 ]
Chen, Wei [1 ]
Xu, Da-chun [1 ]
Xu, Ya-wei [1 ]
机构
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Cardiol, Sch Med, Shanghai 200072, Peoples R China
基金
中国国家自然科学基金;
关键词
cardiac hypertrophy; dual specific phosphatase 12; c-Jun N-terminal kinase (JNK); signalling pathway; SP600125; N-TERMINAL KINASE; HEART-FAILURE; ACTIVATION; REGULATORS; CARDIOMYOPATHY; IDENTIFICATION; APOPTOSIS; REVEALS; BINDING; ERK1/2;
D O I
10.1042/CS20160664
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pathological cardiac hypertrophy is an independent risk factor of heart failure. However, we still lack effective methods to reverse cardiac hypertrophy. DUSP12 is a member of the dual specific phosphatase (DUSP) family, which is characterized by its DUSP activity to dephosphorylate both tyrosine and serine/threonine residues on one substrate. Some DUSPs have been identified as being involved in the regulation of cardiac hypertrophy. However, the role of DUSP12 during pathological cardiac hypertrophy is still unclear. In the present study, we observed a significant decrease in DUSP12 expression in hypertrophic hearts and cardiomyocytes. Using a genetic loss-of-function murine model, we demonstrated that DUSP12 deficiency apparently aggravated pressure overload-induced cardiac hypertrophy and fibrosis as well as impaired cardiac function, whereas cardiac-specific overexpression of DUPS12 was capable of reversing this hypertrophic and fibrotic phenotype and improving contractile function. Furthermore, we demonstrated that JNK1/2 activity but neither ERK1/2 nor p38 activity was increased in the DUSP12 deficient group and decreased in the DUSP12 overexpression group both in vitro and in vivo under hypertrophic stress conditions. Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice. DUSP12 protects against pathological cardiac hypertrophy and related pathologies. This regulatory role of DUSP12 is primarily through c-Jun N-terminal kinase (JNK) inhibition. DUSP12 could be a promising therapeutic target of pathological cardiac hypertrophy. DUSP12 is down-regulated in hypertrophic hearts. An absence of DUSP12 aggravated cardiac hypertrophy, whereas cardiomyocyte-specific DUSP12 overexpression can alleviate this hypertrophic phenotype with improved cardiac function. Further study demonstrated that DUSP12 inhibited JNK activity to attenuate pathological cardiac hypertrophy.
引用
收藏
页码:141 / 154
页数:14
相关论文
共 33 条
[1]   Unrestrained p38 MAPK Activation in Dusp1/4 Double-Null Mice Induces Cardiomyopathy [J].
Auger-Messier, Mannix ;
Accornero, Federica ;
Goonasekera, Sanjeewa A. ;
Bueno, Orlando F. ;
Lorenz, John N. ;
van Berlo, Jop H. ;
Willette, Robert N. ;
Molkentin, Jeffery D. .
CIRCULATION RESEARCH, 2013, 112 (01) :48-+
[2]   Redox Regulation of the Human Dual Specificity Phosphatase YVH1 through Disulfide Bond Formation [J].
Bonham, Christopher A. ;
Vacratsis, Panayiotis O. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (34) :22853-22864
[3]   The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44(MAPK) cascade [J].
Brondello, JM ;
Brunet, A ;
Pouyssegur, J ;
McKenzie, FR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (02) :1368-1376
[4]   The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo [J].
Bueno, OF ;
De Windt, LJ ;
Lim, HW ;
Tymitz, KM ;
Witt, SA ;
Kimball, TR ;
Molkentin, JD .
CIRCULATION RESEARCH, 2001, 88 (01) :88-96
[5]   Epidemiology and risk profile of heart failure [J].
Bui, Anh L. ;
Horwich, Tamara B. ;
Fonarow, Gregg C. .
NATURE REVIEWS CARDIOLOGY, 2011, 8 (01) :30-41
[6]   Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter [J].
Ekerot, Maria ;
Stavridis, Marios P. ;
Delavaine, Laurent ;
Mitchell, Michael P. ;
Staples, Christopher ;
Owens, David M. ;
Keenan, Iain D. ;
Dickinson, Robin J. ;
Storey, Kate G. ;
Keyse, Stephen M. .
BIOCHEMICAL JOURNAL, 2008, 412 :287-298
[7]   Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy [J].
Ferguson, Bradley S. ;
Harrison, Brooke C. ;
Jeong, Mark Y. ;
Reid, Brian G. ;
Wempe, Michael F. ;
Wagner, Florence F. ;
Holson, Edward B. ;
McKinsey, Timothy A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (24) :9806-9811
[8]   Regulation of cardiac hypertrophy by intracellular signalling pathways [J].
Heineke, Joerg ;
Molkentin, Jeffery D. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2006, 7 (08) :589-600
[9]   The IκB Kinase β/Nuclear Factor κB Signaling Pathway Protects the Heart From Hemodynamic Stress Mediated by the Regulation of Manganese Superoxide Dismutase Expression [J].
Hikoso, Shungo ;
Yamaguchi, Osamu ;
Nakano, Yuko ;
Takeda, Toshihiro ;
Omiya, Shigemiki ;
Mizote, Isamu ;
Taneike, Manabu ;
Oka, Takafumi ;
Tamai, Takahito ;
Oyabu, Jota ;
Uno, Yoshihiro ;
Matsumura, Yasushi ;
Nishida, Kazuhiko ;
Suzuki, Keiichiro ;
Kogo, Mikihiko ;
Hori, Masatsugu ;
Otsu, Kinya .
CIRCULATION RESEARCH, 2009, 105 (01) :70-79
[10]   The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling [J].
Ji, Yan-Xiao ;
Zhang, Peng ;
Zhang, Xiao-Jing ;
Zhao, Yi-Chao ;
Deng, Ke-Qiong ;
Jiang, Xi ;
Wang, Pi-Xiao ;
Huang, Zan ;
Li, Hongliang .
NATURE COMMUNICATIONS, 2016, 7